Cohort Studyhigh evidence
Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy.
JAMA·July 20, 2026·PMID 42475062
Why it mattersThe 2026 guideline substantially broadens statin eligibility, particularly among lower-risk, younger adults. Cardiologists and primary care clinicians will need to understand these shifts to implement risk-based discussions and manage the increased volume of statin candidates, balancing population benefit against individual risk and resource implications.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled